Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 433
- Registration Number
- NCT04997837
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-07-15
- Target Recruit Count
- 66
- Registration Number
- NCT04963088
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 12
- Registration Number
- NCT04942626
- Locations
- 🇩🇪
University Hospital Goethe University Frankfurt, Frankfurt, Germany
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT04940546
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Perioperative Chemotherapy in Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Ukrainian Society of Clinical Oncology
- Target Recruit Count
- 69
- Registration Number
- NCT04937738
- Locations
- 🇺🇦
National Cancer Institute, Kyiv, Ukraine
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT04933227
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Beijing Cancer Hospital, Beijing, China
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
- Conditions
- Interventions
- Procedure: AnoscopyProcedure: Biospecimen CollectionProcedure: ColonoscopyDrug: CapecitabineProcedure: Computed TomographyProcedure: Digital Rectal ExaminationProcedure: EchocardiographyBiological: NivolumabProcedure: ProctoscopyOther: Fludeoxyglucose F-18Other: Questionnaire AdministrationDrug: FluorouracilProcedure: SigmoidoscopyRadiation: Intensity-Modulated Radiation TherapyProcedure: Lymph Node BiopsyProcedure: Magnetic Resonance ImagingDrug: MitomycinProcedure: Positron Emission Tomography
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT04929028
- Locations
- 🇺🇸
Zuckerberg San Francisco General Hospital, San Francisco, California, United States
🇺🇸George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 150
- Registration Number
- NCT04908813
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT04895358
- Locations
- 🇺🇸
Parkview Research Center at Parkview Regional Medical Center ( Site 0071), Fort Wayne, Indiana, United States
🇺🇸University of Illinois at Chicago ( Site 0061), Chicago, Illinois, United States
🇫🇷Institut de Cancérologie de l'Ouest ( Site 0915), ANGERS cedex 02, Maine-et-Loire, France
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- EBG MedAustron GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT04894643
- Locations
- 🇦🇹
EBG MedAustron GmbH, Wiener Neustadt, Niederösterreich, Austria
🇦🇹Department of Surgery, LK Wiener Neustadt, Wiener Neustadt, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.